Arrowhead Research | ARWR - Fremdkapital

Aktienkurs
65.55
Täglich Wechseln
-0.68 -1.03%
Monatlich
12.82%
Jährlich
455.98%
Q2 Prognose
59.19




Fremdkapital Veränderung Datum
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
Arrowhead Research USD 538.1M 323.22M 2025-12
Heron Therapeutics USD 140.64M 975K 2025-12
Incyte USD 30.2M 5.17M 2025-12
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
Ligand Pharmaceuticals USD 445.49M 445.44M 2025-09
Merck USD 39.97B 6B 2025-09
Moderna USD 610M 584M 2025-12
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Novartis USD 29.59B 5.35B 2025-12
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
TG Therapeutics USD 245.64M 305K 2025-12
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09
Vertex Pharmaceuticals USD 111.4M 1.4M 2025-03
Xencor USD 76.48M 11.29M 2025-12